Gastroenterology
Volume 138, Issue 1 , Pages 147-158.e1 , January 2010

Serum Fibrosis Markers Identify Patients With Mild and Progressive Hepatitis C Recurrence After Liver Transplantation

  • José A. Carrión

      Affiliations

    • Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERehd, Barcelona, Spain
    • ,
  • Guillermo Fernández–Varo

      Affiliations

    • Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona, Spain
    • ,
  • Miquel Bruguera

      Affiliations

    • Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERehd, Barcelona, Spain
    • Corresponding Author InformationReprint requests Address requests for reprints to: Miquel Navasa, Liver Unit, Hospital Clinic, IDIBAPS, Ciberehd, Villarroel 170, 08036 Barcelona, Spain. fax: +34 93 451 5522
    • ,
  • Juan–Carlos García–Pagán

      Affiliations

    • Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERehd, Barcelona, Spain
    • ,
  • Juan–Carlos García–Valdecasas

      Affiliations

    • Liver Transplantation and Hepatic Surgery Department, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona, Spain
    • ,
  • Sofía Pérez–Del–Pulgar

      Affiliations

    • Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERehd, Barcelona, Spain
    • ,
  • Xavier Forns

      Affiliations

    • Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERehd, Barcelona, Spain
    • ,
  • Wladimiro Jiménez

      Affiliations

    • Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona, Spain
    • ,
  • Miquel Navasa

      Affiliations

    • Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERehd, Barcelona, Spain

Received 16 January 2009 ,Accepted 16 September 2009.

References 

  1. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–687
  2. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250–256
  3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–896
  4. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746–1756
  5. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–836
  6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457
  7. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43:492–499
  8. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey (For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF)). Hepatology. 2000;32:477–481
  9. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847
  10. Rigamonti C, Donato MF, Fraquelli M, et al. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. Gut. 2008;57:821–827
  11. Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl. 2006;12:1791–1798
  12. Benlloch S, Berenguer M, Prieto M, Rayon JM, Aguilera V, Berenguer J. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl. 2005;11:456–462
  13. Toniutto P, Fabris C, Bitetto D, et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol. 2007;22:1904–1908
  14. Pungpapong S, Nunes DP, Krishna M, et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl. 2008;14:1294–1302
  15. Cisneros L, Londono MC, Blasco C, et al. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transpl. 2007;13:1017–1027
  16. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem. 1996;42:558–563
  17. Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol. 1995;22:22–26
  18. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–1713
  19. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455–460
  20. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. 2009;136:160–167
  21. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008;48:1549–1557
  22. Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res. 2008;32:1031–1039
  23. Fontana RJ, Bonkovsky HL, Naishadham D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009;7:219–226
  24. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol. 2009;50:719–728
  25. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39:389–396
  26. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology. 2004;40:699–707
  27. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25:658–663
  28. Martinez SM, Dominguez M, Fernandez-Varo G, et al. Performance of non-invasive methods in the assessment of disease severity in routine clinical practice in patients with chronic hepatitis C. Hepatology. 2007;46:318A–319A
  29. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–374
  30. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–843
  31. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl. 2007;13:219–226
  32. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679–687
  33. Navasa M, Forns X. How accurately and how early can we predict rapid fibrosis progression in hepatitis C virus-infected patients after liver transplantation?. Liver Transpl. 2008;14:1237–1239
  34. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004;126:529–540

 Conflicts of interest X.F. received unrestricted grant support from Schering and Roche, and J.A.C. received a grant from Fundación BBVA. The other authors disclose no conflicts.

 Funding Miquel Navasa received support from Instituto de Salud Carlos III (PI050230); Xavier Forns received support from Instituto de Salud Carlos III (PI080239); Wladimiro Jiménez received support from Dirección General de Investigación Científica y Técnica (SAF09-08839); José A. Carrión received a grant from Fundación BBVA. The authors thank Siemens Healthcare Diagnostics (Tarrytown, NY) for generously supplying the reagents to measure the fibrosis markers.

PII: S0016-5085(09)01697-7

doi: 10.1053/j.gastro.2009.09.047

Gastroenterology
Volume 138, Issue 1 , Pages 147-158.e1 , January 2010

Article Tools

* Image Usage & Resolution